THURSDAY, Jan. 23, 2014 (HealthDay News) -- Women who start
hormone replacement therapy after having had hip or knee
replacement surgery may cut their risk of needing another procedure
in the same joint by nearly 40 percent, a new study suggests.
About 2 percent of those who have a hip or knee replacement need
another surgery within three years. Most of these additional
procedures are needed because of a complication known as
osteolysis, which happens when tiny pieces of the implant seep into
the tissue around the implant, causing inflammation that destroys
the bone around the implant, the British researchers explained.
"There is evidence that drugs like hormone replacement therapy, used usually to prevent osteoporosis and fractures, might have a beneficial effect on implant survival in patients undergoing knee or hip replacement," said lead researcher Dr. Nigel Arden, director of musculoskeletal epidemiology at the University of Oxford in England.
"These findings must be confirmed in further studies, but they are consistent with previous reports by our group showing an association between use of other drugs that have similar effects on bone and the risk of implant revision [surgery]," he said.
However, many women are nervous about taking hormone replacement
therapy because of previously reported increased risks for heart
disease and cancer. Since the risk of a second surgery is small,
the question remains whether or not it's worth starting hormone
replacement therapy at all.
"Indeed, this is only a small added benefit of hormone replacement therapy. However, it is a relevant piece of information for women who have received a total knee or hip replacement and are considering hormone replacement therapy for menopausal symptoms," Arden said.
The report was published online Jan. 22 in the
Annals of the Rheumatic Diseases.
For the study, Arden and his colleagues collected data on more
than 21,000 women who had not used hormone replacement therapy
after a hip or knee replacement. The investigators compared these
women with more than 3,500 women who had taken hormone replacement
therapy for at least six months after surgery.
The researchers found that women who had taken hormone
replacement therapy for six months after surgery were 38 percent
less likely to need another surgery than those who had not.
Moreover, women who took hormone replacement therapy for a year
or more after surgery were more than 50 percent less likely to need
another surgery over three years of follow-up.
Taking hormone replacement therapy before joint replacement,
however, didn't make a difference in the risk for a repeat
procedure, the researchers noted.
Dr. Neil Roth, an orthopedic surgeon at Lenox Hill Hospital in
New York City, thinks there may be a role for drugs that help build
and strengthen bone after knee and hip replacement surgeries. Based
on this study, hormone replacement therapy might also be helpful,
Roth noted, however, that this study only showed an association,
and not a cause-and-effect link, between hormone replacement
therapy and a lowered risk for another surgery.
"Right now, I wouldn't make any changes in the way I clinically treat things based on this study, but I think it deserves further investigation," he added.
U.S. National Institute of Arthritis and
Musculoskeleta...nd Skin Diseasesfor more on joint replacement
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.